Serum Metabolomic Signatures Predict Tumor Recurrence After Resection or Ablation in Patients with Early-stage Hepatocellular Carcinoma

We generated serum metabolome profiles in patients with early-stage hepatocellular carcinoma (BCLC stage 0/A) who achieved complete response to surgical resection or local ablation at University of Texas Southwestern Medical Center and Parkland Health between 2015 and 2023. Normalized abundance of 19 unique metabolites was determined using ultra high-performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS) performed by Metabolon, Inc.